Mobile

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabe...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-009500-39

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To estimate the difference in change in HbA1c from the randomization visit (visit 2) to endpoint (30 weeks) between 2 regimens: BET (basal insulin Glargine, Exenatide BID and metformin) and BBT (basal insulin Glargine, bolus insulin insulin TID and metformin) in subjects with type 2 diabetes and inadequate glycemic control (HbA1c > 7.0%) pretreated with basal insulin Glargine in combination with metformin or in combination with metformin and sulfonylurea (SU).

Critère d'inclusion

  • diabetes

Liens